CoChat

Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial

Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H.‐H., Vaag, A. · 2007 · Diabetes, Obesity and Metabolism
Cited by 44

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim: Metformin is the ‘drug‐of‐first‐choice’ in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non‐obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator‐initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non‐obese patients with T2DM. Methods: A single‐centre, double‐masked, double‐dummy, crossover study during 2 × 4 months involved 96 non‐obese (body mass index ≤ 27 kg/m 2 ) insulin‐naïve patients with T2DM. At enrolment, previous oral hypoglycaemic agents (OHA) were stopped and patients entered a 1‐month run‐in on diet‐only treatment. Hereafter, patients were randomized to either repaglinide 2 mg thrice daily followed by metformin 1 g twice daily or vice versa each during 4 months with 1‐month washout between interventions. Results: End‐of‐treatment levels of haemoglobin A 1c (HbA 1c ), fasting plasma glucose, mean of seven‐point home‐monitored plasma glucose and fasting levels of high‐sensitivity C‐reactive protein and adiponectin were not significantly different between treatments. However, body weight, waist circumference, fasting serum levels of insulin and C‐peptide were lower and less number of patients experienced hypoglycaemia during treatment with metformin vs. repaglinide. Both drugs were well tolerated. Conclusions: In non‐obese patients with T2DM, overall glycaemic regulation was equivalent with less hypoglycaemia during metformin vs. repaglinide treatment for 2 × 4 months. Metformin was more effective targeting non‐glycaemic cardiovascular risk markers related to total and abdominal body fat stores as well as fasting insulinaemia. These findings may suggest the use of metformin as the preferred OHA also in non‐obese patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00713.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 44

Metadata

Authors
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. ‐., & Vaag, A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2007-03
Volume
9
Issue
3
Pages
394-407
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1969296390
Cited by
44
References
12
FWCI
3.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00713.x
The paper
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. ‐., & Vaag, A. (2007). Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00713.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.